CD8A and neoplasm: In addition, another group showed that CD38 expression is increased following therapy with a PD-L1 inhibitor in a lung cancer mouse model, which was associated with impaired CD8+ T-cell function, and the combination of a CD38 antibody with PD-L1 inhibitor showed enhanced anti-tumor activity [61].